http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1817004-A2
Outgoing Links
Predicate | Object |
---|---|
assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f84747e8d08b1023763356d0e7d1db68 |
classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1278 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1273 |
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1272 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-132 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-127 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-704 |
filingDate | 2005-11-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a4ddf58cf4d95cff3429a31f35561ecd http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5328c59bfc6171fd16195573a7ccde72 |
publicationDate | 2007-08-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | EP-1817004-A2 |
titleOfInvention | Combination therapy associating preferably a ceramide with a cytotoxic drug |
abstract | The present invention concerns a new medical treatment involving the combination of two active entities, as well as pharmaceutical compositions comprising the two active entities. Specifically, the invention provides a pharmaceutical composition comprising a stable lipid assembly comprising as a first active entity an apoptosis-affecting lipid which does not self-aggregate in a polar environment to form liposomes and a lipopolymer. The pharmaceutical composition further comprises, as the second active entity, a cytotoxic amphipathic weak base drug carried by the lipid assembly or by a different liposome. According to one embodiment, the apoptotic-affecting lipid is a pro-apoptotic lipid. A preferred pro-apoptotic lipid is ceramide, preferably C6-ceramide. The cytotoxic amphipathic weak base drug is preferably doxorubicin or a biologically active, anthracyline-based doxorubicin analog thereof. |
priorityDate | 2004-11-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 292.